Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Dyslipidaemia in 2013

New statin guidelines and promising novel therapeutics

Nature Reviews Cardiology volume 11, pages 72–74 (2014)Cite this article

Subjects

The new ACC/AHA guidelines on treatment of blood cholesterol focus on intensity of statin therapy rather than target levels of lipids. Early studies show substantial reductions in LDL-cholesterol level with antibodies against PCSK9. MicroRNA silencing and gene-repair techniques to treat dyslipidaemia are promising strategies under development.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: microRNA maturation and gene repression.

References

  1. Stone, N. J. et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation http://dx.doi.org/10.1161/01.cir.0000437738.63853.7a.

  2. Desai, N. R. et al. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of NCEP-ATP III LDL-C goals among high risk patients: an analysis from the LAPLACE-TIMI 57 trial. J. Am. Coll. Cardiol. http://dx.doi.org/10.1016/j.jacc.2013.09.048.

  3. Cohen, J. C., Boerwinkle, E., Mosley, T. H. Jr & Hobbs, H. H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354, 1264–1272 (2006).

    Article  CAS  Google Scholar 

  4. Desai, N. R. et al. AMG 145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy. Circulation 128, 962–969 (2013).

    Article  CAS  Google Scholar 

  5. Stein, E. A. et al. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 128, 2113–2120 (2013).

    Article  CAS  Google Scholar 

  6. Koren, M. J. et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia. Circulation http://dx.doi.org/10.1161/CIRCULATIONAHA.113.007012.

  7. McKenney, J. M. et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J. Am. Coll. Cardiol. 59, 2344–2353 (2012).

    Article  CAS  Google Scholar 

  8. Rotllan, N., Ramírez, C. M., Aryal, B., Esau, C. C. & Fernández-Hernando, C. Therapeutic silencing of microRNA-33 inhibits the progression of atherosclerosis in Ldlr−/− mice—brief report. Arterioscler. Thromb. Vasc. Biol. 33, 1973–1977 (2013).

    Article  CAS  Google Scholar 

  9. Eberlé, D. et al. Inducible Apoe gene repair in hypomorphic ApoE mice deficient in the low-density lipoprotein receptor promotes atheroma stabilization with a human-like lipoprotein profile. Arterioscler. Thromb. Vasc. Biol. 33, 1759–1767 (2013).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Biochemistry (Vascular Prevention Clinic), Royal Free Hospital Campus, University College School of Medicine, Pond Street, London, NW3 2QG, UK

    Dimitri P. Mikhailidis

  2. Atherosclerosis and Metabolic Syndrome Outpatient Units, Medical School, Aristotle University of Thessaloniki, Hippokration Hospital, 15 Marmara Street, Thessaloniki, 55132, Greece

    Vasilios G. Athyros

Authors
  1. Dimitri P. Mikhailidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vasilios G. Athyros
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dimitri P. Mikhailidis.

Ethics declarations

Competing interests

D. P. Mikhailidis declares that he has given talks, attended conferences, and participated in trials and advisory boards sponsored by Genzyme and MSD. V. G. Athyros declares no competing interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mikhailidis, D., Athyros, V. New statin guidelines and promising novel therapeutics. Nat Rev Cardiol 11, 72–74 (2014). https://doi.org/10.1038/nrcardio.2013.209

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrcardio.2013.209

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing